1 October 2014 in Plastic and Reconstructive Surgery
Background: First reported in 1969, buttocks implant surgery has evolved greatly since the introduction of the intramuscular technique. This technique provides good implant coverage and protects the sciatic nerve from compression. However, it enables the occurrence of a new complication, intramuscular hernia or implant displacement. The goal of this research study is to describe, classify, and standardize the treatment of gluteal implant displacement. Methods: The treatment algorithm was developed after dissection of fresh human cadavers and analysis of computed tomographic scans in patients with implant displacement. After elaborating the treatment protocol for implant displacement, it was prospectively applied in 24 patients that presented with visible implants. Results: Intramuscular dissection has proven to be technically possible when a minimum of 2 cm of muscle thickness is achieved. One-stage surgery was applied in 41 buttocks (21 patients). The control computed tomographic scan obtained 3 months after surgery has shown fibrosis in the buttocks area, corresponding to the subcutaneous capsule housing the implant in the anomalous position. The operative wound complications were more frequent, and treatment failure with relapse of the implant superficial displacement occurred in only one of 47 buttocks (2.1 percent). Conclusions: The treatment of gluteal implant displacement can be a one-stage surgical procedure for most patients. This decision is based on the thickness of the gluteus maximus muscle just below the implant. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
5 October 2021 in JCO Global Oncology
PURPOSE: Non–small-cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 80%-90% of the cases. In Brazil, between 2018 and 2019, lung cancer was ranked as the second most frequent cancer among men and the fourth among women. The primary objectives were to describe the journey and survival rates of patients with advanced NSCLC treated in the Brazilian private health care system (HCS). MATERIALS AND METHODS: A retrospective cohort study was based on the search in administrative databases to analyze the Brazilian private HCS. Patients with advanced NSCLC diagnosed between 2011 and 2016 were included. The data on demographics, cancer-related information, treatment-related information, and resources used were collected. Survival analyses were performed using the semiparametric Kaplan-Meier method to assess mortality by NSCLC stage, with NSCLC diagnosis as the index date. RESULTS: A total of 5,016 patients were included. Most patients were between 60 and 69 years old (33.6%) and had completed elementary school (52.2%). There was a greater proportion of men (58.1% v 41.9%), and the majority of patients had stage IV NSCLC (67%). It took an average of 31 days, from the first consultation, to have diagnosis. In 44% of the cases, a clinical oncologist was the first specialist in the HCS that the patient was referred to. After the diagnosis, the median time to start of treatment was 35 days. Chemotherapy alone was the most common treatment regimen (32%). The median overall survival was 11.5 months and 6 months for stage II and IV NSCLC, respectively. CONCLUSION: This study provides contemporary data on stage III and IV NSCLC in private health care in Brazil, which has shown a high rate of metastatic disease diagnoses, high health care–related costs, and low survival rates.